Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In the Health Care segment, the company expects to expand sales of new Medical products and broaden its sales regions, as well as increase new Pharma projects. In the QOL segment, it will expand sales of high-value-added grades; in the Nutrition segment, sales of reduced CoQ10 products; and in the Material segment, it will stabilize spreads and expand sales of high-value-added products. The company expects geopolitical conditions and the market environment to remain uncertain.
Litigation-related expenses: ¥645 million; product warranty expenses: ¥1,285 million; total extraordinary losses: ¥1,930 million
| Item | Details |
|---|---|
| Net Sales | ¥820,000 million → ¥890,000 million（+8.5%） |
| Operating profit | ¥36,000 million → ¥48,000 million（+33.3%） |
| Ordinary income | ¥32,000 million → ¥41,500 million（+29.7%） |
| Profit attributable to owners of the parent | ¥31,500 million → ¥32,000 million（+1.6%） |
| Net income per share | 523.04 Yen and sen → 536.33 Yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Fiscal Period Covered Fiscal year ending March 2026 / Net Sales 811,638 Millions of yen (yen and sen for net income per share) / Operating profit 32,894 Millions of yen (yen and sen for net income per share) / Ordinary income 28,873 Millions of yen (yen and sen for net income per share) / Profit attributable to owners of the parent 30,977 Millions of yen (yen and sen for net income per share) / Net income per share 501.26 Millions of yen (yen and sen for net income per share) |
| Reason for the revision | In the Health Care segment, the company expects to expand sales of new Medical products and broaden its sales regions, as well as increase new Pharma projects. In the QOL segment, it will expand sales of high-value-added grades; in the Nutrition segment, sales of reduced CoQ10 products; and in the Material segment, it will stabilize spreads and expand sales of high-value-added products. The company expects geopolitical conditions and the market environment to remain uncertain. |
| Details and amount of extraordinary loss | Litigation-related expenses: ¥645 million; product warranty expenses: ¥1,285 million; total extraordinary losses: ¥1,930 million |
| Dividend forecast revision | The year-end dividend was increased from the previous forecast of ¥105 to ¥110, and the full-year dividend forecast was revised from ¥210 to ¥215. |
| Consolidated / non-consolidated | Consolidated |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company expects new Medical products in the Health Care segment and expansion into additional sales regions, an increase in new Pharma projects, and expanded sales of reduced CoQ10 products in the Nutrition segment. It is also pursuing wider sales of high-value-added products, price revisions and spread stabilization, while stating that uncertainty remains over geopolitical conditions and the market environment.